- Home
- APM vs ALBT Comparison
APM vs ALBT Comparison
Compare APM & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- ALBT
- Stock Information
- Founded
- APM 2010
- ALBT 2014
- Country
- APM United Kingdom
- ALBT United States
- Employees
- APM N/A
- ALBT N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APM Health Care
- ALBT Health Care
- Exchange
- APM Nasdaq
- ALBT Nasdaq
- Market Cap
- APM 6.7M
- ALBT 5.7M
- IPO Year
- APM 2018
- ALBT N/A
- Fundamental
- Price
- APM $0.94
- ALBT $2.57
- Analyst Decision
- APM
- ALBT
- Analyst Count
- APM 0
- ALBT 0
- Target Price
- APM N/A
- ALBT N/A
- AVG Volume (30 Days)
- APM 34.1K
- ALBT 104.6K
- Earning Date
- APM 07-22-2025
- ALBT 08-18-2025
- Dividend Yield
- APM N/A
- ALBT N/A
- EPS Growth
- APM N/A
- ALBT N/A
- EPS
- APM N/A
- ALBT N/A
- Revenue
- APM N/A
- ALBT $807,235.00
- Revenue This Year
- APM N/A
- ALBT N/A
- Revenue Next Year
- APM N/A
- ALBT N/A
- P/E Ratio
- APM N/A
- ALBT N/A
- Revenue Growth
- APM N/A
- ALBT N/A
- 52 Week Low
- APM $0.46
- ALBT $2.11
- 52 Week High
- APM $7.49
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- APM 47.15
- ALBT 37.26
- Support Level
- APM $0.86
- ALBT $2.52
- Resistance Level
- APM $1.01
- ALBT $2.74
- Average True Range (ATR)
- APM 0.06
- ALBT 0.28
- MACD
- APM -0.01
- ALBT -0.01
- Stochastic Oscillator
- APM 41.16
- ALBT 5.15
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.